All In Biotech

Drug Trial Radar · NCT00734864

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma

Last checked: Nov 19, 2026Latest source record: Nov 21, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 2009

Primary completion

Jun 2010

Study completion Jun 2012

Sponsor

Lead sponsor
Annick DesjardinsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bristol-Myers Squibb
First posted
Aug 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of dasatinib when combined with protracted, daily temozolomide (TMZ). Secondary objectives are: To further evaluate the safety and tolerability of dasatinib plus protracted, daily TMZ; 2. To evaluate the pharmacokinetics of dasatinib when administered with protracted, daily TMZ among recurrent malignant glioma patients who are on and not on CYP-3A enzyme inducing anti-epileptic drugs (EIAEDs); 3. To evaluate for anti-tumor activity with this regimen in this patient population.

Conditions

  • Glioblastoma Multiforme
  • Gliosarcoma
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Glioma

Interventions

  • enzyme-inducing anti-epileptic drugsDrug

    Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).

  • enzyme-inducing anti-epileptic drugsDrug

    Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Toxicity assessed using CTCAE v.3.0Time frame: weekly

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.